|163.68||+6.14||+3.90%||Vol 7.29M||1Y Perf 65.99%|
|Apr 16th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||162.25||Analyst Rating||Moderate Buy 1.78|
|Potential %||-0.87||Finscreener Ranking||★★★+ 51.69|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★+ 49.11|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★★+ 63.36|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Market Cap||36.16B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||98.68||Earnings Date||5th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||3.11|
|EPS Growth Next 5 Years %||16.00|
|Avg. Weekly Volume||2.89M|
|Avg. Monthly Volume||2.13M|
|Avg. Quarterly Volume||2.59M|
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) stock closed at 163.68 per share at the end of the most recent trading day (a 3.9% change compared to the prior day closing price) with a volume of 7.31M shares and market capitalization of 36.16B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3837 people. Alexion Pharmaceuticals Inc. CEO is Ludwig N. Hantson.
The one-year performance of Alexion Pharmaceuticals Inc. stock is 65.99%, while year-to-date (YTD) performance is 4.76%. ALXN stock has a five-year performance of 6.92%. Its 52-week range is between 94.82 and 164.6, which gives ALXN stock a 52-week price range ratio of 98.68%
Alexion Pharmaceuticals Inc. currently has a PE ratio of 57.20, a price-to-book (PB) ratio of 2.91, a price-to-sale (PS) ratio of 7.32, a price to cashflow ratio of 11.40, a PEG ratio of 2.32, a ROA of 3.24%, a ROC of 7.65% and a ROE of 5.04%. The company’s profit margin is -0.32%, its EBITDA margin is 16.50%, and its revenue ttm is $4.63 Billion , which makes it $21.04 revenue per share.
Of the last four earnings reports from Alexion Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $3.11 for the next earnings report. Alexion Pharmaceuticals Inc.’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Alexion Pharmaceuticals Inc. is Moderate Buy (1.78), with a target price of $162.25, which is -0.87% compared to the current price. The earnings rating for Alexion Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Alexion Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Alexion Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 8.32, ATR14 : 3.16, CCI20 : 410.65, Chaikin Money Flow : -0.14, MACD : 0.76, Money Flow Index : 64.33, ROC : 6.67, RSI : 68.00, STOCH (14,3) : 92.84, STOCH RSI : 1.00, UO : 64.50, Williams %R : -7.16), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Alexion Pharmaceuticals Inc. in the last 12-months were: Daniel A. Bazarko (Sold 0 shares of value $-2 816 740 ), Daniel A. Bazarko (Sold 24 066 shares of value $3 795 233 ), Indrani Lall Franchini (Sold 6 853 shares of value $785 981 ), Tanisha Carino (Sold 1 530 shares of value $187 058 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.